[{"id":"04df3049-aecf-4362-a49a-2285288f64a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05075993","created_at":"2021-10-13T16:58:12.200Z","updated_at":"2024-07-02T16:35:11.360Z","phase":"Phase 1","brief_title":"Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors","source_id_and_acronym":"NCT05075993","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD40","pipe":"","alterations":" ","tags":["CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • albumin-bound paclitaxel • cyclophosphamide • cyclophosphamide intravenous • dalnicastobart (LVGN7409) • exlinkibart (LVGN6051) • pradusinstobart (LVGN3616)"],"overall_status":"Recruiting","enrollment":" Enrollment 352","initiation":"Initiation: 11/12/2021","start_date":" 11/12/2021","primary_txt":" Primary completion: 02/02/2027","primary_completion_date":" 02/02/2027","study_txt":" Completion: 02/02/2027","study_completion_date":" 02/02/2027","last_update_posted":"2024-04-04"},{"id":"60707de4-d68b-43d2-b8f8-d68e859d0321","acronym":"","url":"https://clinicaltrials.gov/study/NCT05301764","created_at":"2022-03-31T19:54:37.938Z","updated_at":"2024-07-02T16:35:37.037Z","phase":"Phase 1/2","brief_title":"A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma","source_id_and_acronym":"NCT05301764","lead_sponsor":"Lyvgen Biopharma Holdings Limited","biomarkers":" TMB • MSI • IFNG • IL6 • TNFA • TNFRSF9","pipe":"","alterations":" ","tags":["TMB • MSI • IFNG • IL6 • TNFA • TNFRSF9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • exlinkibart (LVGN6051)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 05/25/2022","start_date":" 05/25/2022","primary_txt":" Primary completion: 03/19/2025","primary_completion_date":" 03/19/2025","study_txt":" Completion: 10/19/2025","study_completion_date":" 10/19/2025","last_update_posted":"2023-09-14"}]